[1] Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet, 2012, 9822: 1245-1255.
[2] Chen WQ,Zheng QS,Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 2: 115-132.
[3] Gilroy E. The influence of arginine upon the growth rate of a transplantable tumour in the mouse. Biochem J, 1930, 3: 589-595.
[4] Gerner EW, Meyskens FL Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer, 2004. 10: 781-792.
[5] Wada S, Matsushita Y, Tazawa H, et al. Loss of p53 in stromal fibroblasts enhances tumor cell proliferation through nitric-oxide-mediated cyclooxygenase 2 activation. Free Radic Res, 2015, 3: 269-278.
[6] Dillon BJ, Prieto VG, Curley SA, et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying comcers sensitive to arginine deprivation. Cancer, 2004, 4: 826-833.
[7] Feun LG, Marini A, Walker G, et al. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer, 2012, 9: 1481-1485.
[8] Szlosarek PW, Klabatsa A, Pallaska A, et al. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res, 2006, 23: 7126-7131.
[9] Szlosarek PW, Fennell DA, Rudd RM, et al. 221 A randomized phase II trial of pegylated arginine deaminase (ADI-PEG 20) in patients with malignant pleural mesothelioma. Lung Cancer, 2006: S54.
[10] Delage B, Luong P, Maharaj L, et al. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis, 2012,7: e342.
[11] Lan J, Tai HC, Lee SW, et al. Deficiency in expression and epigenetic DNA Methylation of ASS1 gene in nasopharyngeal carcinoma: negative prognostic impact and therapeutic relevance. Tumor Biol, 2014, 1: 161-169.
[12] Kim RH, Coates JM, Bowles TL, et al. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res, 2009, 2: 700-708.
[13] Syed N, Langer J, Janczar K, et al. Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis, 2013,1: e458.
[14] Nicholson LJ, Smith PR, Hiller L, et al. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum‐induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer, 2009, 6: 1454-1463.
[15] Allen MD, Luong P, Hudson C, et al. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res, 2014, 3: 896-907.
[16] Qiu F, Chen YR, Liu X, et al. Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. Sci Signal, 2014, 319: ra31.
[17] Yoon CY, Shim YJ, Kim EH, et al. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer, 2007, 4: 897-905.
[18] Lagarde SM, Ver Loren van Themaat PE, Moerland PD, et al. Analysis of gene expression identifies differentially expressed genes and pathways associated with lymphatic dissemination in patients with adenocarcinoma of the esophagus. Ann Surg Oncol, 2008, 12: 3459-3470.
[19] Tsai WB, Aiba I, Lee S, et al. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1α/Sp4. Mol Cancer Ther, 2009, 12: 3223-3233.
[20] Kelly MP, Jungbluth AA, Wu BW, et al. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase. Br j Cancer, 2012, 2: 324-332.
[21] Bowles TL, Kim R, Galante J, et al. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer, 2008, 8: 1950-1955.
[22] Huang HY, Wu WR, Wang YH, et al. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin Cancer Res, 2013, 11: 2861-2872.
[23] Izzo F, Marra P, Beneduce G, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol, 2004,10:1815-1822.
[24] Wang S, Tsun ZY, Wolfson RL, et al. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science, 2015, 6218: 188-194.
[25] Bach SJ, Simon-Reuss I. Arginase, an antimitotic agent in tissue culture. Biochim Biophys Acta, 1953, 953: 396-402.
[26] Holtsberg FW, Ensor CM, Steiner MR, et al. Poly (ethylene glycol)(PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J Control Release, 2002, 1: 259-271.
[27] Lam TL, Wong GK, Chong HC, et al. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest. Cancer Lett, 2009, 1: 91-100.
[28] Cheng PN, Lam TL, Lam WM, et al. Pegylated recombinant human arginase (rhArg-peg5, 000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res, 2007, 1: 309-317.
[29] Yau T, Cheng PN, Chan P, et al. A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Invest New Drugs, 2013, 1: 99-107.
[30] Glazer ES, Piccirillo M, Albino V, et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol, 2010, 13: 2220-2226.
[31] Yang TS, Lu SN, Chao Y, et al. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br j Cancer, 2010, 7: 954-960.
[32] Long Y, Tsai WB, Wangpaichitr M, et al. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Mol Cancer Ther, 2013, 11: 2581-2590.
[33] Rodríguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev, 2008, 1: 180-191.
[34] Rabinovich S, Adler L, Yizhak K, et al. Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. Nature, 2015, 7578: 379-383. |
